10 analysts have shared their evaluations of HealthEquity
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 7 | 1 | 0 | 0 |
| Last 30D | 1 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $110.9, with a high estimate of $125.00 and a low estimate of $94.00. Observing a downward trend, the current average is 1.47% lower than the prior average price target of $112.56.
The standing of HealthEquity among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Allen Lutz | B of A Securities | Raises | Buy | $125.00 | $110.00 |
| Constantine Davides | JMP Securities | Raises | Market Outperform | $117.00 | $110.00 |
| Daniel Perlin | RBC Capital | Announces | Outperform | $112.00 | - |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $100.00 | $110.00 |
| Alexander Paris | Barrington Research | Maintains | Outperform | $112.00 | $112.00 |
| David Roman | Goldman Sachs | Lowers | Neutral | $94.00 | $107.00 |
| C. Gregory Peters | Raymond James | Lowers | Strong Buy | $115.00 | $120.00 |
| Scott Schoenhaus | Keybanc | Lowers | Overweight | $110.00 | $120.00 |
| Alexander Paris | Barrington Research | Maintains | Outperform | $112.00 | $112.00 |
| Alexander Paris | Barrington Research | Maintains | Outperform | $112.00 | $112.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to HealthEquity. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of HealthEquity compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of HealthEquity's stock. This analysis reveals shifts in analysts' expectations over time.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.